Vancouver, British Columbia, Dec. 21, 2020 (GLOBE NEWSWIRE) -- The global nanopharmaceutical drugs market is projected to be worth USD 82.71 Billion by 2027, according to the current analysis by Emergen Research. The nanopharmaceutical drugs market is observing a high demand attributed to the growing burden of chronic diseases, such as cancer, cardiovascular diseases, and immunological diseases across the globe. The WHO (World Health Organization) has released statistics that indicate that the burden of chronic diseases is projected to grow by 57.0% by the year 2020 from 2001. Developing nations are expected to be highly impacted, contributing to 60.0% of the global burden of chronic diseases.
An increase in healthcare expenditure and increased funding for healthcare R&D are significantly driving the nanopharmaceutical drugs market growth. The healthcare expenditure in the U.S. reached USD 3.60 trillion in 2018, an increase of 4.6% from the previous year. This rise in spending is, to some extent, faster as compared to the increase in 2017 from 2016.
Get your FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.emergenresearch.com/request-sample-form/378
Key Highlights From The Report
- In September 2020, Tottenham Acquisition I Limited made an announcement about signing a merger contract with Clene Nanomedicine, Inc., a biopharmaceutical company involved in the development of a potential therapeutic nanocatalyst for treating neurodegenerative diseases, as well as nanotechnology based-therapy for microbial infections.
- Solid lipid nanoparticles are beneficial in controlling and targeting drug release. It offers advantages, such as excellent biocompatibility, enhanced pharmaceuticals' stability, high and increased drug content, easy sterilization, and enhanced scalability.
- The protein-based nanopharmaceutical drugs sub-segment is estimated to account for a market valuation of USD 14.00 ± 7.00 billion, and the market size for nucleic acid-based nanopharmaceuticals is likely to be USD 7.00 ± 3.00 billion in the year 2020.
- Several academic research laboratories are continually making advancements in the field of nanopharmaceutical, resulting in increased demand for nanopharmaceutical drugs.
- The Asia Pacific region is forecast to grow with the fastest CAGR during the period 2020-2027. The increased investment by public as well as private firms for the development of healthcare infrastructure and in R&D of nanopharmaceutical drugs are augmenting the growth of the market.
- Key participants include Amgen Inc., AstraZeneca PLC, Gilead Sciences Inc., Novartis AG, F. Hoffmann-La Roche AG, AbbVie Inc., Johnson & Johnson, Pfizer Inc., Sanofi SA, and Merck & Co. Inc., among others.
ORDER NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.emergenresearch.com/select-license/378
Emergen Research has segmented the Global Nanopharmaceutical Drugs Market on the basis of type, application, distribution channel, and region:
- Type Outlook (Revenue, USD Billion; 2017-2027)
- Liposomes
- Polymeric Micelles
- Microemulsion
- Solid Lipid Nanoparticles
- Nanoemulsion
- Others
- Application Outlook (Revenue, USD Billion; 2017-2027)
- Oncology
- Cardiovascular/Physiology
- Anti-inflammatory/Immunology
- Neurology
- Anti-Infective
- Others
- Distribution Channel Outlook (Revenue, USD Billion; 2017-2027)
- Hospital Pharmacies
- Retail Off-Line Pharmacies
- Retail On-Line Pharmacies
To identify the key trends in the industry and read full summary click on the link: https://www.emergenresearch.com/industry-report/nanopharmaceutical-drugs-market
- Regional Outlook (Revenue, USD Billion; 2017-2027)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- BENELUX
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- U.A.E.
- Rest of MEA
- North America
Take a Look at our Related Reports:
In Silico Drug Discovery Market By Workflow (Discovery, Preclinical Tests, Clinical Trials), By Product (Consultancy as a Service, Software as a Service), By Type of Large Molecule, By End User (Contract Research Organizations, Pharmaceutical Industry), and By Region, Forecasts to 2027
Human Microbiome Modulators Market By Product (Prebiotics and Dietary Supplements, Probiotics and Creams, Drugs), By Application (Infections, Neurological Disorders, Cancers, Dermatological, Gastrointestinal, Metabolic), By Region Forecasts to 2027
Intelligent Drug Discovery Market By Offering (Software, Services), By Technology (Machine Learning, Other Technologies), By Application (Neurodegenerative Diseases, Metabolic Diseases, Immuno-Oncology), By End User (Contract Research Organizations), and By Region, Forecasts to 2027
About Emergen Research
Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com
Facebook | LinkdIn | Twitter | Blogs
Read Full Press Release@ https://www.emergenresearch.com/press-release/global-nanopharmaceutical-drugs-market